2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-116030
    JNJ-26076713 669076-03-3 98%
    JNJ-26076713 is a potent and orally active alpha V integrin antagonist with IC50 values of 2.3 nM and 6.3 nM for alpha(V)beta(3) and alpha(V)beta(5), respectively. JNJ-26076713 inhibits retinal neovascularization.
    JNJ-26076713
  • HY-116031
    ATC0175 free base 509118-03-0 98%
    ATC0175 (free base) is a potent and selective antagonist of melanin-concentrating hormone receptor 1 (MCH-R1) with an IC50 value of 3.4 nM, as well as good selectivity over the Y5 and the α2A receptors. ATC0175 (free base) is promising for research of obesity.
    ATC0175 free base
  • HY-116095
    CypD-IN-5 1572646-93-5 98%
    CypD-IN-5 (compound C-9) is a potent cyclophilin D (CypD) inhibitor. CypD-IN-5 can be used in the study of Alzheimer's disease.
    CypD-IN-5
  • HY-116169
    KUC-7322 255734-04-4 98%
    KUC-7322, a selective β3 -adrenoceptor agonist, is the active form of ritobegron. Ritobegron decreases intravesical pressure with minimal effects on the cardiovascular system.
    KUC-7322
  • HY-116198
    15-PGDH-IN-2 1221413-57-5 98%
    15-PGDH-IN-2 (Compound 2) is a 15-PGDH inhibitor with an IC50 value of 0.274 nM. 15-PGDH-IN-2 can be used in research on hair loss, bone formation, gastric ulcer healing, and dermal wound healing.
    15-PGDH-IN-2
  • HY-116241
    L-157012 114801-28-4 98%
    L-157012 is a HMG-CoA reductase (HMGCR) inhibitor. L-157012 is also a cholesterol-lowering agent.
    L-157012
  • HY-116379
    RS-100329 232953-52-5 98%
    RS-100329 is an α1-adrenergic receptor (α1-AR) antagonist that effectively inhibits α1-adrenergic receptor-mediated contractions of lower urinary tract tissues in vitro and in vivo. RS-100329 can be used in the research of symptoms related to benign prostatic hyperplasia.
    RS-100329
  • HY-116433
    Nequinate 13997-19-8 98%
    Nequinate, a quinoline compound, is an anticoccidial agent against cecal coccidiosis (Eimeria tenella) infections. Nequinate inhibits xanthine oxidoreductase (XOD) activity.
    Nequinate
  • HY-116521
    SR2595 1415252-61-7 98%
    SR2595 is an inverse agonist of PPARγ with an IC50 of 30 nM.
    SR2595
  • HY-116546
    Sch 40853 129672-23-7 98%
    Sch 40853 is a active metabolite of SCH 39166 (HY-14690) and can be used for the research of schizophrenia and obesity.
    Sch 40853
  • HY-116595
    J-104118 172277-82-6 98%
    J-104118 is a potent and orally active squalene synthase (SQS) inhibitor with an IC50 of 0.52 nM. J-104118 inhibits cholesterol synthesis in mice. J-104118 can be used for cholesterol-lowering research.
    J-104118
  • HY-116630
    Usistapide 403989-79-7 98%
    Usistapide (JNJ-16269110) is a microsomal triglyceride transfer protein (MTP) inhibitor. Usistapide is promising for research of obesity.
    Usistapide
  • HY-116640
    Amorphigenin 4208-09-7 98%
    Amorphigenin is a trothotenone compound. Amorphigenin inhibits osteoclast differentiation by suppressing the expression of c-Fos and NFATc1 in activated T cells. Amorphigenin degrades melanosome proteins by activating the AMPK-dependent autophagy pathway, but not in dependence of the mTOR pathway. Amorphigenin significantly protects bone mass and reduces bone erosion in a mouse model of inflammatory bone loss. Amorphigenin can be used to study inflammatory bone diseases, postmenopausal osteoporosis, and skin pigmentation disorders.
    Amorphigenin
  • HY-116694
    Digallic acid 536-08-3 98%
    Digallic acid is an antioxidant, antimutagenic, antigenotoxic, and anti-hyperuricemic compound. Digallic acid is a reverse transcriptase and XOD, URAT1 (IC50: 5.34 μM) inhibitor. Digallic acid scavenges DPPH· and O2·− radicals. Digallic acid induces apoptosis. Digallic acid can be isolated from the fruits of Pistascia lentiscus.
    Digallic acid
  • HY-116696
    GSK3-IN-11 681432-07-5 98%
    GSK3-IN-11 is a Glycogen Synthase Kinase-3 (GSK-3) inhibitor with an IC50 of 5010 nM.
    GSK3-IN-11
  • HY-116725
    Glipentide 32797-92-5 98%
    Glipentide is a sulfonylurea receptor agonist. Glipentide increases the concentration of fructose-2,6-bisphosphate in rat hepatocytes and inhibits basal gluconeogenesis. Glipentide can reduce glycerol production in rat adipose tissue. Glipentide can be used in research on endocrine and metabolic diseases such as diabetes.
    Glipentide
  • HY-116776
    Hexadecatetraenoic acid 29259-52-7 98%
    Hexadecatetraenoic acid is an unsaturated fatty acid that can be isolated from sardine oil.
    Hexadecatetraenoic acid
  • HY-116844
    Glymidine 339-44-6 98%
    Glymidine (Glidiazine) is a hypoglycaemic agent. Glymidine is a lipid soluble sulphapyrimidine derivative. Glymidine appears to stimulate insulin release from pancreas. Glymidine is a possible alternative to the sulphonylureas and biguanides for the research of diabetes mellitus.
    Glymidine
  • HY-116923
    p18SMI-21 20535-76-6 98%
    p18SMI-21 is a novel INK4C inhibitor that specifically blocks the biological activity of p18 protein. p18SMI-21 exerts its anti-gastric acid effect through direct contact, and the intensity of this effect varies with the dose. p18SMI-21 can significantly reduce the proteolytic activity of pepsin under certain conditions. The inhibitory effect of p18SMI-21 is best achieved in direct contact with the substrate. If it contacts the substrate first, the inhibitory effect will be lost.
    p18SMI-21
  • HY-116946
    Glucokinase activator 6 480463-02-3 98%
    Glucokinase activator 6 (compound 9) is a potent glucokinase activator, with an EC50 of 0.09 μM. Glucokinase activator 6 can be used for type 2 diabetes (T2D) research.
    Glucokinase activator 6
Cat. No. Product Name / Synonyms Application Reactivity